The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.

In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.

The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.